Assessment of differentially methylated loci in individuals with end-stage kidney disease attributed to diabetic kidney disease: an exploratory study

Table 1 Participant group characteristics, per comparison

	Analysis 1*	Analysis 2	Analysis 3*	Analysis 4
Cases
Number of participants	107	107	73	73
Diagnosis	T1DM with ESKD (transplant recipients or dialysis)	T1DM with ESKD (transplant recipients or dialysis)	T1DM with ESKD (transplant recipients only)	T1DM with ESKD (transplant recipients only)
Number of F:M	43:64	43:64	26:47	26:47
Average Age (St. Dev.)	41.7 years (9.7)	41.7 years (9.7)	40.5 years (9.3)	40.5 years (9.3)
Average duration of T1DM (St. Dev.)	29.1 years (6.5)	29.1 years (6.5)	30.1 years (5.7)	30.1 years (5.7)
Controls
Number of participants	107	253	73	253
Diagnosis	Long-duration of T1DM with no evidence of kidney disease	Long-duration of T1DM with no evidence of kidney disease	Long-duration of T1DM with no evidence of kidney disease	Long-duration of T1DM with no evidence of kidney disease
Number of F:M	43:64	121:132	26:47	121:132
Average Age (St. Dev.)	41.2 years (10.2)	41.2 years (9.6)	40.1 years (9.1)	41.2 years (9.6)
Average duration of T1DM (St. Dev.)	26.8 years (7.9)	26.3 years (7.4)	25.5 years (7.8)	26.3 years (7.4)

ESKD end-stage kidney disease, F females, M males, St. Dev. standard deviation, T1DM type 1 diabetes
*Analyses 1 and 3: Matched cases and controls for sex, average age (≤ 5 years) and duration of diabetes (≤ 10 years)

ISSN: 1868-7083